WSGR logoWSGR logo
Blake Torrance
Patent Agent
Patents and Innovations
Washington, D.C.

D617-598-7884

Download vCard
Open PDF

Dr. Blake Torrance is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His broad scientific expertise includes immunology, vaccine development, infectious disease, and the biology of aging.

Blake completed his doctoral training in immunology at the University of Connecticut Health Center. His research focused on the effects of aging on the immune response to influenza infection and vaccination. This work also investigated the use of various anti-aging interventions to improve immune responses and the development of immune memory. Prior to his graduate studies, his work included the identification and characterization of cancer immunotherapies and the effects of gut microbes on tumor progression.

Experience

Dr. Blake Torrance is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His broad scientific expertise includes immunology, vaccine development, infectious disease, and the biology of aging.

Blake completed his doctoral training in immunology at the University of Connecticut Health Center. His research focused on the effects of aging on the immune response to influenza infection and vaccination. This work also investigated the use of various anti-aging interventions to improve immune responses and the development of immune memory. Prior to his graduate studies, his work included the identification and characterization of cancer immunotherapies and the effects of gut microbes on tumor progression.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Upsized Public Offering
On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases, announced the pricing of its upsized underwritten public offering. The company is offering 5,555,557 shares at $13.50 per share and, in lieu of shares to investors that so choose, pre-funded warrants to purchase up to 3,703,730 shares at $13.4999. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares. The gross proceeds from this offering, to be closed on or about April 2, are expected to be $125 million before expenses. Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters related to the transaction.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.